Navigation Links
ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012
Date:2/21/2012

SKILLMAN, N.J., Feb. 21, 2012 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announces that Ken Berger will assume the position of CEO, ConvaTec, and will be appointed to the ConvaTec Board of Directors.

Berger joins ConvaTec from Thermo Fisher Scientific where he spent the last ten years, most recently as Senior Vice President and Group President of the Specialty Diagnostics Group, a global $2 billion high-value diagnostics business.  "We are excited to have Ken take over the helm of ConvaTec," said Toni Weitzberg, Chairman of the Board of Directors for ConvaTec.  "His track record of building highly profitable businesses, combined with diverse global experience and a history of building strong leadership teams is well suited to take ConvaTec to the next level of performance excellence."

"I am pleased to work with Nordic Capital and Avista Capital Partners as CEO of ConvaTec," said Berger, "and I look forward to working with the ConvaTec team to realize the incredible potential of this business."

This appointment follows the mutual agreement between David I. Johnson and the ConvaTec Board of Directors that he will step down as CEO, effective March 5, 2012.  "Dave successfully managed the carve-out from Bristol Myers Squibb Co. and created an independent global company with a strong platform for growth," stated Weitzberg. "The Board thanks him for his service in leading ConvaTec over the past six years, and for his dedication to the Company for over twelve years."

"I am proud to leave this fine organization with a strengthened financial foundation, renewed growth momentum; and of course, a continued commitment to the company mission," said Johnson.  "I am confident that the entire organization is ready to take ConvaTec to even greater heights."

Over the next sixty days, Johnson will work with the Board and his successor to ensure an orderly transition of leadership.

About ConvaTecConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit www.convatec.com.Contacts: Media Relations: Investor Relations:Nimisha Savani Tim WinstonVP, Corporate Affairs VP, TreasurerConvaTec

ConvaTec908-904-2522

908-904-2988mediarelations@convatec.com  

investorrelations@convatec.com


'/>"/>

SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ConvaTec Healthcare Announces 2011 Third Quarter Earnings Call
2. ConvaTec Announces Acquisition of Farnhurst Medical
3. ConvaTec Announces Acquisition of Boston Medical Device
4. ConvaTec Healthcare Announces 2011 Second Quarter Earnings Call
5. ConvaTec Announces Asia-Pacific Leadership Appointments
6. Preliminary Results of a Large Scale Study Show ConvaTec Moldable Technology™ Skin Barriers Help to Prevent and Improve Peristomal Skin Issues in Ostomy Patients
7. ConvaTec Healthcare Announces 2011 First Quarter Earnings Call
8. ConvaTec Presents New Data on ConvaTec Moldable Technology™ and Vitala™ Continence Control Device in Ostomy Care
9. ConvaTec Announces Acquisition of Trent Direct
10. ConvaTec Healthcare Announces 2010 Year-End Earnings Call
11. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... Dec. 6, 2016 Human Vaccines Market: ... region wise and country wise analysis of the ... manufacturers of human vaccines products, raw material suppliers, ... enter the market. The report provides qualitative ... market. Qualitative analysis comprises market dynamics, trends, product ...
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million ... suffer from the epidemic of diabetes. 1 However, ... persistently elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... serious complications, including cardiovascular events. If left untreated, hyperglycemia ... and eye disease or blindness. 3 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, ... is painful for her. "This is why the co-inventor and I have designed a ... They then created a prototype of the patent-pending AV-AIR, a device that serves as ...
(Date:12/7/2016)... ... XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... Man’s ... Filamentous Dermatitis Associated with Borrelia Infection” reveals that a condition similar ... the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease is ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Facial plastic ... this holiday season by donating a portion of proceeds to two local organizations: North ... Chicago Animal Control & Friends is a team of authorized and trained volunteers ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
Breaking Medicine News(10 mins):